Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Current Liabilities (2024 - 2025)

Historic Total Current Liabilities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $18.2 million.

  • Prelude Therapeutics' Total Current Liabilities fell 1815.15% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year decrease of 1815.15%. This contributed to the annual value of $25.6 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Prelude Therapeutics' Total Current Liabilities is $18.2 million, which was down 1815.15% from $20.9 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Total Current Liabilities registered a high of $25.6 million during Q4 2024, and its lowest value of $17.6 million during Q1 2024.